Characteristics | All | Low risk exacerbator (LRE) | High risk exacerbator (HRE) | PFT I | PFT II |
---|---|---|---|---|---|
Number of patients | 78 | 60 | 18 | 43 | 35 |
Age (years) | |||||
 Range | 40–93 | 40–91 | 52–93 | 40–90 | 52–93 |
 Mean ± s.e.m | 74.17 ± 1.446 | 73.63 ± 1.673 | 75.94 ± 2.889 | 72.37 ± 2.020 | 76.37 ± 2.025 |
Gender | |||||
 Male | 68 (87.2%) | 50 (83.3%) | 18 (100%) | 36 (83.7%) | 32 (91.4%) |
 Female | 10 (12.8%) | 10 (16.7%) | 0 (0%) | 7 (16.3%) | 3 (8.6%) |
FEV1 (% predicted) | |||||
 Range | 24.6–97.9 | 30.5–97.9 | 24.6–73.8 | 50.0–97.9 | 24.6–49.6 |
 Mean ± s.e.m | 53.24 ± 1.682 | 55.73 ± 1.902 | 44.95 ± 2.901 | 63.62 ± 1.702 | 40.49 ± 1.097 |
FEV1/FVC | |||||
 Range | 37.31–69.54 | 45.33–69.54 | 37.31–66.86 | 52.30–69.54 | 37.31–69.18 |
 Mean ± s.e.m | 59.59 ± 0.767 | 60.98 ± 0.783 | 54.95 ± 1.673 | 62.45 ± 0.738 | 56.07 ± 1.218 |
Current smoking | |||||
 No | 17 (21.8%) | 13 (21.7%) | 4 (22.2%) | 11 (25.6%) | 6 (17.1%) |
 Yes | 61 (78.2%) | 47 (78.3%) | 14 (77.8%) | 32 (74.4%) | 29 (82.9%) |
Medication | |||||
 LAB | 31 (39.7%) | 28 (46.7%) | 3 (16.7%) | 28 (65.1%) | 3 (8.6%) |
 LABA + ICS | 45 (57.7%) | 30 (50.0%) | 15 (83.3%) | 13 (30.2%) | 32 (91.4%) |
 No | 2 (2.6%) | 2 (3.3%) | 0 (0%) | 2 (4.7%) | 0 (0%) |